Background: In the EMBRACA phase III trial, talazoparib (1 mg daily, orally) demonstrated a statistically significant improvement in PFS versus physician's choice of chemotherapy (PCT; capecitabine, eribulin, gemcitabine, or vinorelbine) in patients with HER2-negative advanced breast cancer carrying a germline BRCA1/2 mutation; we evaluated patient-reported outcomes (PROs).
Introduction
In EMBRACA (NCT01945775), the efficacy and safety of the PARP inhibitor talazoparib were compared with that of physician's choice of chemotherapy (PCT) for the treatment of human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) in patients with a germline BRCA1/2 mutation (gBRCA1/2m). Primary results showed statistically significant improvement in progression-free survival (PFS) versus PCT [1] .
Therapies that control cancer also aim to maintain quality of life (QoL); however, drug-related toxicity could reduce QoL among patients with ABC [2] . The maintenance or improvement of QoL is an important goal in ABC, where treatment is palliative. When evaluating new treatments, it is therefore imperative to consider the importance of patient-reported outcomes (PROs) as an integral component of benefit-risk assessment. Such measurements are necessary when determining the quality of the time gained by delaying disease progression. Previously, we reported top-level results of the impact of talazoparib therapy on global health status (GHS)/QoL [1] . We report detailed cancer-related and breast cancer-specific PROs from EMBRACA.
Methods

Study design and participants
The EMBRACA study [1] was an open-label, randomized, international, phase III trial comparing the efficacy, safety, and PROs of talazoparib (1 mg daily, orally) with PCT (capecitabine, eribulin, gemcitabine, or vinorelbine) using a 2 : 1 randomization in patients with locally advanced/metastatic breast cancer (supplementary Figure S1 , available at Annals of Oncology online).
PRO assessments
PROs were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30, version 3.0) and its QLQ-BR23 breast cancer module, at day 1 (baseline), the start of each treatment cycle (every 3 weeks), and the end of treatment.
The EORTC QLQ-C30 comprises five multi-item functional subscales, three multi-item symptom scales, a GHS/QoL subscale, and six singleitem symptom scales assessing other disease and/or treatment-related symptoms [3] . The EORTC QLQ-BR23 is breast cancer-specific module comprising four functional scales and four symptom scales. Responses to all items are converted to a 0-100 scale using a standard scoring algorithm [4] . For functional and GHS/QoL scales, higher scores represent a better level of functioning and QoL. For symptom scales, a higher score represents a higher severity of symptoms. Hence, a negative change from baseline in symptom scales reflects an improvement and a positive change reflects a deterioration. Conversely, a negative change from baseline in functional and GHS/QoL scales reflects a deterioration and a positive change reflects an improvement.
Statistical analyses
All PRO analyses presented are prespecified and exploratory and were based on PRO-evaluable patients, defined as those in the intention-totreat (ITT) population with a baseline assessment and at least one postbaseline assessment before the end of study treatment. Completion rates were summarized. Higher scores indicated better GHS/QoL or functioning, or higher symptom severity.
The main PRO analysis was based on a longitudinal mixed-effect model with treatment, time, treatment by time, and baseline as covariates. This analysis was carried out on the observed values and the changes from baseline for EORTC QLQ-C30 and QLQ-BR23 scales. Analysis of time to definitive clinically meaningful deterioration (TTD) in all functional and symptom scales was also carried out; definitive clinically meaningful deterioration in GHS/QoL and functional scales was defined as the time from randomization to the first observation with a !10-point decrease and no subsequent observations with a <10-point decrease from baseline. Definitive clinically meaningful deterioration in the symptom scales was defined as the time from randomization to the first observation with a !10-point increase and no subsequent observations with a <10-point increase from baseline. The 10-point threshold was chosen based on previously established thresholds for minimally important differences from the perspective of the patient [5] . Patients not meeting deterioration criteria were censored at the time of last available PRO assessment. Survival analysis methods included the Kaplan-Meier approach for estimating medians and percentiles and the Brookmeyer and Crowley method for computing 95% confidence intervals (CIs), assuming proportional hazards for computing hazard ratio (HR), and using the log-rank test in comparing TTD between treatment arms. No adjustments were made for multiplicity. All analyses were conducted using Statistical Analysis System software (SAS Institute; Cary, NC); P values were two-sided.
Results
The ITT population comprised 431 patients [287 were assigned to receive talazoparib and 144 to receive PCT (capecitabine, 44%; eribulin, 40%; gemcitabine, 10%; vinorelbine, 7%; percentages total >100% due to rounding up of values)]; 18 (12.5%) patients who were randomized to receive PCT withdrew consent without being treated versus one patient in the talazoparib arm (supplementary Figure S1 and Table S1 , available at Annals of Oncology online).
For every cycle from baseline to Cycle 13, !81% of patients in the talazoparib arm and !73% in the PCT arm completed at least one question on the EORTC QLQ-C30; similarly, !81% and !73% of patients, respectively, completed at least one question on the EORTC QLQ-BR23 (supplementary Tables S2 and S3 , available at Annals of Oncology online).
Patient-reported GHS/QoL
Baseline mean scores for GHS/QoL were similar in the talazoparib and PCT arms [61.9 (95% CI 59.0, 64.7) versus 60.9 (95% CI 56.9, 64.9), respectively]. Baseline scores in the study were within range of reference values published previously [6] in patients with recurrent or metastatic breast cancer ( Table 1) .
The between-treatment comparison based on a repeatedmeasures mixed-effect model showed a statistically significant difference between the two treatment arms in GHS/QoL scores, favoring talazoparib [difference, 8.4 (95% CI 4.6, 12.3); P < 0.0001; Figure 1A ].
As shown in Figure 2a , based on interpretation from the 95% CIs, a statistically significant improvement in overall change from baseline was observed in the talazoparib arm A significantly greater delay in TTD of GHS/QoL was observed in the talazoparib arm [24.3 months; 95% CI 13.8, not reached (NR)] versus the PCT arm (6.3 months; 95% CI 4.9, 12.2), with an HR of 0.376 (95% CI 0.26, 0.55; P < 0.0001; Figure 3A ).
Patient-reported functional scales (QLQ-C30)
Baseline scores for all five QLQ-C30 functional scales were similar between the two treatment arms, with high functional levels in both (Table 1) .
Between-treatment comparison in the change from baseline scores showed a statistically significant difference favoring talazoparib for all five functional scales ( Figure 1A) .
The overall change from baseline within each treatment arm based on interpretation from the 95% CIs indicated a statistically significant improvement for talazoparib in physical functioning In addition, treatment with talazoparib significantly delayed TTD in all five functional scales compared with the overall PCT arm (supplementary Figure S2 , available at Annals of Oncology online).
Patient-reported symptom scales (QLQ-C30)
Mean baseline scores for the symptom scales of EORTC QLQ-C30 were similar in both treatment arms for all symptoms. Baseline scores for the symptoms indicate low symptom severity in both treatment arms (Table 1) .
Between-treatment comparison in change from baseline scores showed a statistically significant difference favoring talazoparib for the symptoms of fatigue, pain, insomnia, and appetite loss. No statistically significant between-treatment differences were observed for the symptoms of nausea/vomiting, dyspnea, constipation, and diarrhea ( Figure 1B) .
Based on interpretation from the 95% CIs, the overall change from baseline within each treatment arm indicated a statistically significant improvement from baseline in the talazoparib arm in fatigue [À3.9 (95% CI À6.2, À1. The sample sizes for the 'sexual enjoyment' functional scale were smaller than other functional scales because patients were asked to respond to this question only if they responded that they were sexually active in a previous question. The sample sizes for the 'upset by hair loss' symptom scale were smaller than other symptom scales because patients were asked to respond to this question only if they responded that they were experiencing hair loss in a previous question. EORTC, European Organisation for Research and Treatment of Cancer; GHS, global health status; PCT, physician's choice of therapy; PRO, patient-reported outcome; QLQ-BR23, Quality of Life Questionnaire breast cancer module; QLQ-C30, Quality of Life Questionnaire Core 30; QoL, quality of life.
the talazoparib arm (median TTD, 22.7 months; 95% CI 16.9, NR) versus the PCT arm (7.5 months; 95% CI 5.8, 11.1), with an HR of 0.337 (95% CI 0.225, 0.504; P < 0.0001; Figure 3B) ; a significantly greater delay in TTD in fatigue was observed in the talazoparib arm (median TTD, 17.1 months; 95% CI 10.5, 27.1) versus the PCT arm (7.1 months; 95% CI 4.3, 9.6), with an HR of 0.396 (95% CI 0.279, 0.562; P < 0.0001; Figure 3C) ; a significantly greater delay in TTD in nausea/vomiting was observed in the f u n c t io n in g E m o t io n a l f u n c t io n in g C o g n it iv e f u n c t io n in g S o c ia l f u n c t io n in g S e x u a l f u n c t io n in g S e x u a l e n jo y m e n t a F u t u r e p e r s p e c t iv e The sample sizes for the 'sexual enjoyment' functional scale were smaller than other functional scales because patients were asked to respond to this question only if they responded that they were sexually active in a previous question.
b The sample sizes for the 'upset by hair loss' symptom scale were smaller than other symptom scales because patients were asked to respond to this question only if they responded that they were experiencing hair loss in a previous question. CI, confidence interval; EORTC, European Organisation for Research and Treatment of Cancer; GHS, global health status; PCT, physician's choice of therapy; PRO, patient-reported outcome; QLQ-BR23, Quality of Life Questionnaire breast cancer module; QLQ-C30, Quality of Life Questionnaire Core 30; QoL, quality of life.
talazoparib arm (median TTD, NR; 95% CI 24.2, NR) versus the PCT arm (9.9 months; 95% CI 6.2, 15.1), with an HR of 0.415 (95% CI 0.267, 0.644; P < 0.0001; Figure 3D ).
Patient-reported functional scales (QLQ-BR23)
The mean scores of the functional scales of body image, sexual functioning, sexual enjoyment, and future perspective were generally similar in both treatment arms at baseline, except for sexual enjoyment, where the mean baseline scores were higher in the talazoparib arm than in the PCT arm (Table 1) . However, the sample sizes for sexual enjoyment were smaller for both arms (talazoparib: 102; PCT: 41) versus other scales because patients were asked to respond to this question only if they responded that they were sexually active in a previous question (Table 1) .
A statistically significantly greater overall change from baseline favoring the talazoparib arm compared with the PCT arm was observed for body image ( Figure 1A) . No statistically significant between-treatment differences were observed for sexual functioning, sexual enjoyment, and future perspective functional scales.
The overall change from baseline within each treatment arm indicated a significant improvement in the talazoparib arm in body image [3.9 (95% CI 1.6, 6. 
Patient-reported symptom scales (QLQ-BR23)
The mean baseline scores for the symptom scales were similar for both treatment arms. All values from both arms were comparable to the reference values, with the exception of 'upset by hair loss', which was substantially higher in both arms than the reference values. The sample sizes for the 'upset by hair loss' symptom scale were considerably smaller (talazoparib, 59; PCT, 27) than those for the other symptom scales because this question was to be answered only if the patient experienced hair loss (Table 1) .
A statistically significant greater overall change from baseline favoring the talazoparib arm compared with the PCT arm was observed for systemic therapy side-effects, breast symptoms, and arm symptoms. A statistically non-significant between-treatment difference was observed in the symptom scale for 'upset by hair loss' (Figure 1B) .
The overall changes within each treatment arm indicate a significant improvement in the talazoparib arm in breast symptoms [À5.1 (95% CI À6.7, À3.5)] and in arm symptoms [À4.6 (CI À6.5, À2.8)], a significant worsening in the PCT arm for systemic therapy side-effects (5.1 [2.2, 7.9]), and a significant improvement in the PCT arm in 'upset by hair loss' (À24.5 [À46.9, À2.2]) ( Figure 2B ). In assessing 'upset by hair loss', we noted that sample sizes in the PCT arm were <10 after Cycle 3.
Talazoparib significantly delayed TTD in systemic therapy side-effects, breast symptoms, and arm symptoms compared with the overall PCT arm (supplementary Figure S5 , available at Annals of Oncology online). No statistically significant delay in TTD in the 'upset by hair loss' scale was observed.
Discussion
Maintaining QoL in patients with ABC is crucial, especially when testing the efficacy of new therapies. Recently published ESMO Magnitude of Clinical Benefit Scale guidance underscored the importance of a holistic assessment of the value of medicine that includes not only efficacy and safety but also PROs [7] . Data presented herein are the first-ever detailed cancer-related and breast cancer-specific PROs regarding talazoparib in gBRCA1/2m patients with HER2-negative locally advanced or metastatic breast cancer. We show that the favorable efficacy achieved with talazoparib is accompanied by significant overall improvements and a significant delay in TTD in multiple patient-reported GHS/ QoL, functions, and symptoms. Notably, when comparing between arms, none of the analyses yielded statistically significant PRO results favoring the overall PCT arm. Our results further support the positive risk-benefit profile of talazoparib and show that talazoparib does not impose toxicities that interfere with patient QoL.
The fourth ESO-ESMO guidelines for ABC recommended a platinum regimen (if not previously administered and no suitable clinical trial is available) for BRCA-associated triple-negative or endocrine-resistant metastatic breast cancer previously treated with an anthracycline with or without a taxane (in the adjuvant and/or metastatic setting) [8, 9] . This recommendation, based on Tutt et al. [9] , indicated that carboplatin was linked to significantly better objective tumor response rates than docetaxel among a subgroup of gBRCA1/2m patients (N ¼ 43). Nevertheless, it is important to consider the potential QoL effects when treated with platinum-based chemotherapy.
Although some preliminary nonrandomized trial data on the activity of cisplatin in BRCA1m TNBC patients were reported [10] , the EMBRACA study was designed in early 2013 before results from the TNT trial [9] . As such, EMBRACA did not investigate single-agent platinum. It is unclear how PROs of talazoparib would compare with that of platinum-based chemotherapy. To our knowledge, there are no published platinum monotherapy PRO data in breast cancer. A 2013 platinum combination study by Amadori et al. [11] found that patients with ABC who received pemetrexed and carboplatin had significantly greater deterioration in GHS/QoL than those who received vinorelbine and gemcitabine.
Being an open-label trial, the PRO results presented may be subject to patient biases. Nevertheless, there is lack of clear empirical evidence that such biases are sufficient to meaningfully affect results of clinical trials [12] . Although for every cycle from baseline to Cycle 13, !81% and !73% in the talazoparib and PCT arms, respectively, completed at least one question (baseline and post baseline) in each of the EORTC questionnaires, the results may have overrepresented the patients who do well in both treatment arms, since patients who progressed no longer complete the questionnaires.
Patients receiving treatment of ABC may be symptomatic, with significant impairment in daily activity and/or work Definitive clinically meaningful deterioration in GHS/QoL was defined as the time from randomization to the first observation with a !10-point decrease and no subsequent observations with a <10-point decrease from baseline. Definitive clinically meaningful deterioration in the pain, fatigue, and nausea/vomiting scales were defined as the time from randomization to the first observation with a !10-point increase and no subsequent observations with a <10-point increase from baseline. CI, confidence interval; EORTC, European Organisation for Research and Treatment of Cancer; GHS, global health status; NR, not reached; PCT, physician's choice of therapy; PRO, patient-reported outcome; QLQ-C30, Quality of Life Questionnaire Core 30; QoL, quality of life; TALA, talazoparib. productivity [13] . Because disease progression may negatively affect QoL, delaying progression could slow the deterioration of QoL, with the exception of any significant detrimental treatment-related toxicity. A large percentage of patients with ABC with bone metastases feel significant pain and have a high incidence of skeletal-related events [14] . Our results showed that talazoparib therapy led to a significant overall improvement and a significant delay in TTD in pain symptoms compared with PCT.
In the EMBRACA ITT population [1] [per the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03], grade 1 alopecia rates were similar in both arms and higher grade 2 rates were observed in the PCT arm (grade 1: talazoparib 23%, PCT 20%, grade 2: talazoparib 2.4%, PCT 7.9%, grade 3-4: not applicable). In our study, the higher baseline patientreported 'upset by hair loss' scores in both arms (versus reference values) may reflect the younger patient population with a short disease-free interval from last adjuvant chemotherapy dose (which typically causes severe alopecia). On a small sample, a statistically significant overall improvement in patient-reported 'upset by hair loss' was observed in the PCT arm; this may be due to patients' awareness and preparedness of known potential PCT-associated alopecia side-effects, whereas such a toxicity in the context of talazoparib, perceived as a targeted and noncytotoxic drug different from chemotherapy agents, could have been more disappointing. In addition, among the EMBRACA ITT population, anemia rates were higher in the talazoparib arm than in the PCT arm (53% versus 18%, respectively); however, fatigue rates were similar in both arms, per CTCAE (all grades: 50% versus 43%, respectively; grade 3: 1.7% versus 3.2%, respectively; grade 4: none in both arms) [1] . In our study, we observed statistically significant overall improvements in patient-reported fatigue symptoms and a statistically significant delay in TTD in fatigue symptoms favoring the talazoparib arm over the PCT arm; these results suggest that the observed anemia adverse event rates did not detrimentally affect fatigue in patients treated with talazoparib compared with PCT from a patient's perspective.
Favorable GHS/QoL results from another PARP inhibitor [15] among metastatic breast cancer patients with gBRCA1/2m suggest a very encouraging outlook with respect to the effects of PARP inhibitors on QoL. Our observed extensive positive cancer-related and breast cancer-specific PROs support the concept that the superior efficacy and favorable safety profile of talazoparib translate to better QoL compared with PCT in locally advanced and metastatic breast cancer patients carrying the gBRCA1/2m.
